The global botanical drug market size was valued at USD 163 million in 2021 and is expected to be valued at USD 3221 million. The market is expected to grow at a CAGR of 39% during the forecast period (2022–2030). Botanical drugs are used to diagnose, cure, treat, or prevent any kind of disease in humans. The use of botanical drugs is growing in society as people prefer the use of herbal medicines over chemically infused ones. Botanical drugs consist more of natural products and natural substances, which can prevent any harmful side effects to the patient’s body. A large number of researches and development projects are being made in the study, processing, and production of botanical drugs.
The development and research of botanical drugs are approved by global regulatory authorities. A significant development in the product will improve the efficiency and performance of the product and drug while also reducing the frequency of the occurrence of any defects. The market of the botanical drug is already quite known and used as it consists of loyal users, but with sufficient support from the government, vendor, and investment, the potential market could grow tremendously. The global botanical drugs market is segmented based on type, form, application, and region.
Get more information on this report Download Sample Report
The life expectancy of people is increasing, leading to an increased geriatric population size. According to the World Health Organization report, the population of people aging 60 years and above will cross the mark of 2 billion globally by the year 2050. By the same year, China alone is expected to have a population of 120 million people who would be aged above 80 years. This tremendous growth in the expectancy of the population will mean an increase in the prevalence of chronic diseases such as cancer, diabetes, etc.
The presence of chronic diseases can also be a witness in the younger age group, which is also expected to rise by huge numbers. This will lead to more demand for botanical drugs and medicines, owing to their effectiveness and accuracy. This will make the global botanical drugs market grow during the forecast period.
Sometimes, patients suffering from serious chronic disease or pain cannot manage to get through with the conventional treatment approaches as it gets more painful for them to bear. Therefore with the doctor's recommendations, they switch to botanical drugs to relieve the pain of the patients. There is also a high amount of expense associated with the production and making of conventional chemical-infused drugs, which is another reason for the increased preference for botanical drug, which is less costly.
With the advancement in technology and study in the field of botanical drugs, it favors the increased demand for botanical products in the market. Hence, the increased need to treat the patients more effectively and product development in the market will propel the demand for botanical drugs.
There are strict regulations imposed in countries like the U.S and Europe, which prevents the growth of the global botanical drug market growth. Due to the presence of such an inflexible regulatory framework, it gets difficult to provide sufficient incentives for the development process of the botanical drug. And because of the insufficient spending on the development and production, the botanical drugs fail to clear the clinical trial, it lacks to show safety and potency, and thereof restraining the success of the drugs. These regulatory and legal obligations and rules vary from country to country, making it difficult for The Global Botanical Drugs Market to grow and prosper.
The presence of favorable regulatory scenarios in some prominent countries like India, Australia, and South Korea has created a growth opportunity for The Global Botanical Drugs Market. The government of the various developed and developing countries have undertaken initiatives to promote and support the development of natural drugs, which has increased the availability of the same in the different healthcare systems globally. Countries like Australia, South Korea, Nigeria, and India, have constantly been promoting the utilization of natural resources and substances for the treatment and curing of chronic diseases. The World Health Organization also advocates the usage of botanical drugs by investing largely in its research and developments.
These endeavors by the government and global regulatory bodies to reinforce the usage of botanica products create more growth opportunities for the global botanical drugs market.
The impact of the noble coronavirus was witnessed in every nation and every economy. It imposed a severe threat to humankind and society, disrupting the economies across the globe. Strict lockdowns were declared by the government to slow down the rapid spread of the disease, productions were ceased, all work environments closed, public interactions were restricted, and temporary suspension of manufacturing and trading activities across the globe. The implementation of the lockdown and lack of public interaction caused interruption and cut down on the operations of the market of various segments.
The entry of covid-19 into the lives of the population also created a lot of pressure on the healthcare segment of the economy and being more disadvantageous that patients had to be monitored remotely, propelling the demand for solutions to create a cure for the treatment. The demand for healthcare equipment like ventilators, oxygen supply, protective equipment, etc., also grew to meet the demand.
The social distancing norms of the government disrupted the supply chain, and companies and workers were unable to operate the equipment due to government-imposed lockdowns. And with regard to the government regulations, the supply of raw materials for the botanical drug was disrupted, causing hindrances to occur in the Global Botanical Drugs Market.
With increased cases across the globe, the need for medicines and medicinal means also grew considerably. This created potential growth scope for the Global Botanical Drugs Market. In a research article published in September 2020, it was stated that herbal medicines could be risk-free means for the assessment of respiratory diseases and can be used as a treatment means for Covid-19. In April 2020, the Indian Council of Medical Research approved the clinal test of the effects of plant materials on the covid virus. Such initiative taken by global governments and official authorities for healthcare developments leads to the promotion of demand for botanical drugs.
The global botanical drugs market share is segmented based on type, form, and application. Based on type, it is segmented as stem/bark, leaf, and others.
The product of botanical medicines is made using different parts of a plant, like its leaves, stem or bark, flowers, roots, seeds, etc. These are used for the diagnosis and treatment of the patient or consumer. Among the segments done by type, the leaf segment is valued at USD 1725 million at a CAGR of 38% during the forecast period, whereas the stem and bark segment has a valuation of USD 1025 million at a CAGR of 40% during the same forecast period.
Segmentation by form is as tablets, ointment, spray, oral solution, and others. The oral solution is expected to have the maximum revenue share of USD 856 million at a CAGR of 38%, the liquid is one of the oldest means for treatment, and it is preferred extensively, especially among elderly people and children owing to the ease of using it.
Next to oral solutions, the tablets segment is anticipated to have around USD 814 million revenue share at a CAGR of 39%. Tablets are among the widely preferred dosage type. Tablets are generally easy to produce, pack and distribute. It is quick and effective. Tablets also offer accuracy, uniformity in dosage, and stability in the physical and chemical formula. Hence, the production of tablets is generally higher.
As per application, the segmentation is done as pharmaceutical, dermatology, and others. Pharmaceutical has the highest market revenue share, which is anticipated to grow at a CAGR of 39%, reaching a value of USD 2188 million over the forecast period. Botanical drugs have the potential to offer therapeutic measures for some chronic diseases. Chronic degenerative disorders are increasing across the globe, like diabetes, asthma, cancer, cardiac disease, etc. these diseases cumulatively account for more than 70% of global mortality. And most of them are still incurable. Therefore pharmaceutical companies and researchers have shifted their focus on the development of botanical drug products that can provide treatment options in an effective manner. Hence, this leads to an increase in pharmaceutical involvement in the global botanical drug market analysis.
Dermatology is expected to have a share of USD 664 million at a CAGR of 39% during the forecast period. Research activities have shown potential in botanical drugs in addressing dermatological issues. A research article revealed a study for the assessment of the efficacy of botanical moisturizers for usage in redness, infection, inflammation, hyperplasia, etc. which proved to be significantly effective. This could push the demand for botanical drugs in dermatology use.
The market for the botanical drug is segmented into North America, Europe, Asia-Pacific, and the Middle East and Africa, as per region.
Regional Growth Insights Request Sample Pages
Europe is expected to dominate the market during the forecast period. The revenue expectancy of Europe is USD 1024 million at a CAGR of 38% by 2030.
Most of the research and developments taking place in Europe are with focus on the cancer therapeutic potential of botanical drugs. Furthermore, the region also has a high number of cancer cases. It was stated by the WHO that Europe accounts for a quarter of the cancer cases across the globe. The region witnesses around 3.7 million new cancer patients annually. This gives rise to the demand for botanica drugs to look for a potential cure for such chronic diseases.
Apart from that, the European market shifted towards the adoption of traditional plant and herbal-based medicines and medicinal approaches, investing hugely in research and development of botanical drugs and medicines. This results in market growth projectile.
Next to Europe is North America, which is expected to have a share of USD 914 million at a CAGR of 39%. The region is extensively focused on the research and development, and discovery of various potential attributes of botanical drugs. The region's government also takes initiatives to promote botanical products. The presence of organizations like ABDA, whose primary focus is on building strategies to increase and build more public awareness about botanical drugs, adds to the growing scope of the global botanical drug market in the region.
The organization of ABDA also groups up with other research institutes and pharma companies to establish high standards for botanical drugs and their medical usage. The region consists of someone of the most promising markets for botanical drugs like the United States. In the year 2018, the US FDA received more than 800 submissions of botanical investigational new drug applications. Such constant research and development by the region bolster the market for the botanical drug.